EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
- 1.4k Downloads
Efficacies of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung cancer (NSCLC). However, their efficacies were only moderate. Some preclinical studies suggested synergistic effects of bevacizumab to EGFR-TKI in TKI-resistant models.
We retrospectively evaluated clinical efficacy and safety of EGFR-TKI rechallenge with bevacizumab. Rebiopsy was performed on all studied cases to examine T790M-resistant mutation status.
Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. Twenty-two (92 %) patients underwent erlotinib and two (8 %) gefitinib as rechallenge EGFR-TKIs in combination with bevacizumab. Three patients achieved partial response, and 18 had stable disease, resulting in the response rate (RR) of 13 % and disease control rate (DCR) of 88 %, respectively. The median progression-free survival (PFS) was 4.1 [95 % confidence interval (CI) 2.3–4.9] months, and the median overall survival (OS) was 13.5 (95 % CI 9.7–27.4) months. The RR, DCR, median PFS, and median OS for T790M-positive versus T790M-negative were 0 versus 18 % (p = 0.530), 86 versus 88 % (p = 1.00), 3.3 versus 4.1 months (p = 0.048), and 15.1 versus 13.5 months (p = 0.996), respectively. Severe adverse events (≥grade 3): grade 3 of 1 (4 %) rash; grade 3 of 1 (4 %) paronychia; grade 3 of 1 (4 %) hypertension; and grade 3 of 1 (4 %) anemia, were observed.
EGFR-TKI rechallenge with bevacizumab demonstrated higher DCR and modestly longer PFS than historical data on EGFR-TKI rechallenge alone. Its activity was notably higher in T790M-negative population.
KeywordsEGFR mutation EGFR-TKI rechallenge Bevacizumab Acquired resistance T790M
We thank Mr. David Martin for writing support.
Compliance with ethical standards
Conflict of interest
No conflicts of interest.
- 5.Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefPubMedGoogle Scholar
- 9.Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMedGoogle Scholar
- 22.National Comprehensive Cancer Network:NCCN Clinical Practice Guidelines in Oncology—Non-Small Cell Lung Cancer, Version 6.2015. http://www.nccn.org
- 27.Heon S, Nishino M, Goldberg SB et al (2012) Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. J Clin Oncol 30 (suppl; abstr 7525)Google Scholar
- 31.Seto T, Kato T, Nishio M et al (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15:1236–1244CrossRefPubMedGoogle Scholar
- 32.Ichihara E, Hotta K, Nogami N et al (2015) Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol 10:486–491CrossRefPubMedGoogle Scholar
- 35.Nagai Y, Miyazawa H, Huqun et al (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65:7276–7282CrossRefPubMedGoogle Scholar
- 44.Hata A, Katakami N, Yoshioka H et al (2015) Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI). J Thorac Oncol (in press)Google Scholar